ICIS is implementing a process of rolling consultation on all of its pricing methodologies. This consultation paper is part of this formal process and covers all of the ICIS primary price points included in the caprolactam weekly publications.
The consultation asks both general questions about the suitability of the ICIS pricing methodology and questions addressing specific caprolactam market issues.
Click here to view the Caprolactam Methodology Consultation 2023 – GMC2323
ICIS received one response for this consultation.
ICIS was asked whether it should consider changing its methodology to disregard bid and offers and keep CFR NE Asia spot prices unchanged in the absence of deals.
ICIS consulted the market and will not propose any changes to the caprolactam methodology at this time as bid and offers are a fundamental part of the price discovery process, particularly in periods of lower liquidity or in the absence of deals. Any decision to change this methodology will be communicated to subscribers using the usual channels and with the usual notice period.
ICIS continues to welcome any feedback on its caprolactam methodology outside of the formal consultation process.
To provide further comments or feedback please contact William Lemos, Deputy Editorial Director: William.Lemos@icis.com